Study of Ezetimibe and Fenofibrate in Patients With Mixed Hyperlipidemia (0653-036)(COMPLETED)
Phase 3
Completed
- Conditions
- HypercholesterolemiaHypertriglyceridemia
- Registration Number
- NCT00092573
- Lead Sponsor
- Organon and Co
- Brief Summary
The purpose of this study is to assess the cholesterol lowering safety and effectiveness of two investigational drugs in patients with mixed hyperlipidemia (high cholesterol and high triglycerides).
- Detailed Description
The duration of treatment is 48 weeks.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 576
Inclusion Criteria
- High cholesterol and high triglycerides
Exclusion Criteria
- Patient has a condition which, in the opinion of the investigator, might pose a risk to the patient, interfere with participation in the study, or does not meet the additional criteria as required by the study
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Tolerability
- Secondary Outcome Measures
Name Time Method Plasma LDL-C, HDL-C and triglycerides after 12 weeks.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie the synergistic lipid-lowering effects of Ezetimibe and Fenofibrate in mixed hyperlipidemia?
How does the Ezetimibe-Fenofibrate combination compare to statin-fibrate regimens in reducing LDL-C and TG levels in NCT00092573 patients?
Which biomarkers correlate with improved HDL-C or triglyceride response in NCT00092573 Ezetimibe-Fenofibrate trials?
What adverse events were observed in NCT00092573 and how do they align with PPAR-alpha and NPC1L1 inhibitor safety profiles?
What are the current combination therapies for mixed hyperlipidemia beyond Ezetimibe and Fenofibrate in post-2004 clinical practice?